Single-dose Study to Investigate the Plasma PK of KW-6356 and Its Major Metabolite
NCT04190654
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
26
Enrollment
INDUSTRY
Sponsor class
Conditions
Hepatic Impairment
Interventions
DRUG:
KW-6356
Sponsor
Kyowa Kirin, Inc.